nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—CYP3A4—Rosuvastatin—atherosclerosis	0.109	0.211	CbGbCtD
Avanafil—CYP3A4—Ezetimibe—atherosclerosis	0.109	0.211	CbGbCtD
Avanafil—CYP3A4—Simvastatin—atherosclerosis	0.102	0.196	CbGbCtD
Avanafil—CYP3A4—Pravastatin—atherosclerosis	0.0994	0.192	CbGbCtD
Avanafil—CYP3A4—Lovastatin—atherosclerosis	0.0994	0.192	CbGbCtD
Avanafil—PDE5A—penis—atherosclerosis	0.0422	0.366	CbGeAlD
Avanafil—PDE5A—artery—atherosclerosis	0.0195	0.169	CbGeAlD
Avanafil—PDE5A—endothelium—atherosclerosis	0.0165	0.143	CbGeAlD
Avanafil—PDE5A—blood vessel—atherosclerosis	0.0152	0.132	CbGeAlD
Avanafil—PDE5A—connective tissue—atherosclerosis	0.0078	0.0676	CbGeAlD
Avanafil—PDE5A—cardiovascular system—atherosclerosis	0.00678	0.0588	CbGeAlD
Avanafil—Blood glucose increased—Niacin—atherosclerosis	0.00664	0.0193	CcSEcCtD
Avanafil—Upset stomach—Lovastatin—atherosclerosis	0.00604	0.0175	CcSEcCtD
Avanafil—PDE5A—adipose tissue—atherosclerosis	0.00598	0.0519	CbGeAlD
Avanafil—Upset stomach—Simvastatin—atherosclerosis	0.00565	0.0164	CcSEcCtD
Avanafil—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.00493	0.0143	CcSEcCtD
Avanafil—Gastrooesophageal reflux disease—Ezetimibe—atherosclerosis	0.00429	0.0125	CcSEcCtD
Avanafil—Musculoskeletal pain—Lovastatin—atherosclerosis	0.004	0.0116	CcSEcCtD
Avanafil—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.00389	0.0113	CcSEcCtD
Avanafil—Gout—Niacin—atherosclerosis	0.00364	0.0106	CcSEcCtD
Avanafil—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00338	0.00982	CcSEcCtD
Avanafil—Diabetes mellitus—Simvastatin—atherosclerosis	0.00309	0.00896	CcSEcCtD
Avanafil—Breast disorder—Rosuvastatin—atherosclerosis	0.00306	0.00888	CcSEcCtD
Avanafil—Hot flush—Ezetimibe—atherosclerosis	0.00301	0.00873	CcSEcCtD
Avanafil—Menopausal symptoms—Ezetimibe—atherosclerosis	0.00298	0.00866	CcSEcCtD
Avanafil—Influenza—Rosuvastatin—atherosclerosis	0.00293	0.00849	CcSEcCtD
Avanafil—Pain in extremity—Lovastatin—atherosclerosis	0.00287	0.00833	CcSEcCtD
Avanafil—Diabetes mellitus—Niacin—atherosclerosis	0.00283	0.00822	CcSEcCtD
Avanafil—Pain in extremity—Ezetimibe—atherosclerosis	0.00282	0.00817	CcSEcCtD
Avanafil—Bronchitis—Rosuvastatin—atherosclerosis	0.00282	0.00817	CcSEcCtD
Avanafil—Hot flush—Pravastatin—atherosclerosis	0.0026	0.00753	CcSEcCtD
Avanafil—Menopausal symptoms—Pravastatin—atherosclerosis	0.00257	0.00746	CcSEcCtD
Avanafil—Breast disorder—Ezetimibe—atherosclerosis	0.00254	0.00738	CcSEcCtD
Avanafil—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00254	0.00736	CcSEcCtD
Avanafil—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00252	0.0073	CcSEcCtD
Avanafil—Gastritis—Ezetimibe—atherosclerosis	0.00249	0.00723	CcSEcCtD
Avanafil—Haematuria—Rosuvastatin—atherosclerosis	0.00249	0.00722	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00248	0.0072	CcSEcCtD
Avanafil—Influenza—Lovastatin—atherosclerosis	0.00248	0.0072	CcSEcCtD
Avanafil—Sinusitis—Rosuvastatin—atherosclerosis	0.00245	0.00711	CcSEcCtD
Avanafil—Influenza—Ezetimibe—atherosclerosis	0.00243	0.00706	CcSEcCtD
Avanafil—Abdominal discomfort—Lovastatin—atherosclerosis	0.00238	0.0069	CcSEcCtD
Avanafil—Gastritis—Simvastatin—atherosclerosis	0.00238	0.00689	CcSEcCtD
Avanafil—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00226	0.00656	CcSEcCtD
Avanafil—Bronchitis—Simvastatin—atherosclerosis	0.00223	0.00648	CcSEcCtD
Avanafil—Abdominal discomfort—Simvastatin—atherosclerosis	0.00222	0.00645	CcSEcCtD
Avanafil—Nasopharyngitis—Pravastatin—atherosclerosis	0.00217	0.0063	CcSEcCtD
Avanafil—Infestation—Ezetimibe—atherosclerosis	0.00217	0.0063	CcSEcCtD
Avanafil—Infestation NOS—Ezetimibe—atherosclerosis	0.00217	0.0063	CcSEcCtD
Avanafil—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00216	0.00626	CcSEcCtD
Avanafil—Urinary tract infection—Lovastatin—atherosclerosis	0.00215	0.00624	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00214	0.00621	CcSEcCtD
Avanafil—Influenza—Niacin—atherosclerosis	0.00213	0.00618	CcSEcCtD
Avanafil—Influenza—Pravastatin—atherosclerosis	0.0021	0.00609	CcSEcCtD
Avanafil—Angina pectoris—Niacin—atherosclerosis	0.00208	0.00602	CcSEcCtD
Avanafil—Sinusitis—Lovastatin—atherosclerosis	0.00208	0.00602	CcSEcCtD
Avanafil—Mental disorder—Rosuvastatin—atherosclerosis	0.00205	0.00596	CcSEcCtD
Avanafil—Bronchitis—Niacin—atherosclerosis	0.00205	0.00595	CcSEcCtD
Avanafil—Angina pectoris—Pravastatin—atherosclerosis	0.00204	0.00593	CcSEcCtD
Avanafil—Sinusitis—Ezetimibe—atherosclerosis	0.00204	0.00591	CcSEcCtD
Avanafil—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00195	0.00566	CcSEcCtD
Avanafil—Sinusitis—Simvastatin—atherosclerosis	0.00194	0.00563	CcSEcCtD
Avanafil—Oedema peripheral—Ezetimibe—atherosclerosis	0.00192	0.00557	CcSEcCtD
Avanafil—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00191	0.00555	CcSEcCtD
Avanafil—Weight increased—Pravastatin—atherosclerosis	0.00191	0.00554	CcSEcCtD
Avanafil—Flushing—Lovastatin—atherosclerosis	0.00184	0.00535	CcSEcCtD
Avanafil—Urinary tract infection—Pravastatin—atherosclerosis	0.00182	0.00528	CcSEcCtD
Avanafil—Flushing—Ezetimibe—atherosclerosis	0.00181	0.00524	CcSEcCtD
Avanafil—Cough—Rosuvastatin—atherosclerosis	0.00178	0.00516	CcSEcCtD
Avanafil—Angiopathy—Ezetimibe—atherosclerosis	0.00177	0.00513	CcSEcCtD
Avanafil—Immune system disorder—Ezetimibe—atherosclerosis	0.00176	0.0051	CcSEcCtD
Avanafil—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00176	0.00509	CcSEcCtD
Avanafil—Sinusitis—Pravastatin—atherosclerosis	0.00176	0.00509	CcSEcCtD
Avanafil—Myalgia—Rosuvastatin—atherosclerosis	0.00174	0.00504	CcSEcCtD
Avanafil—Arthralgia—Rosuvastatin—atherosclerosis	0.00174	0.00504	CcSEcCtD
Avanafil—Flushing—Simvastatin—atherosclerosis	0.00172	0.005	CcSEcCtD
Avanafil—Mental disorder—Ezetimibe—atherosclerosis	0.00171	0.00495	CcSEcCtD
Avanafil—Malnutrition—Ezetimibe—atherosclerosis	0.0017	0.00492	CcSEcCtD
Avanafil—Oedema peripheral—Niacin—atherosclerosis	0.00168	0.00487	CcSEcCtD
Avanafil—CYP3A4—Irinotecan Pathway—NPC1—atherosclerosis	0.00168	0.08	CbGpPWpGaD
Avanafil—Back pain—Lovastatin—atherosclerosis	0.00167	0.00485	CcSEcCtD
Avanafil—Muscle spasms—Lovastatin—atherosclerosis	0.00166	0.00482	CcSEcCtD
Avanafil—Infection—Rosuvastatin—atherosclerosis	0.00165	0.0048	CcSEcCtD
Avanafil—Back pain—Ezetimibe—atherosclerosis	0.00164	0.00476	CcSEcCtD
Avanafil—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00163	0.00474	CcSEcCtD
Avanafil—Muscle spasms—Ezetimibe—atherosclerosis	0.00163	0.00473	CcSEcCtD
Avanafil—Vision blurred—Lovastatin—atherosclerosis	0.00163	0.00473	CcSEcCtD
Avanafil—Mental disorder—Simvastatin—atherosclerosis	0.00163	0.00472	CcSEcCtD
Avanafil—Eye disorder—Niacin—atherosclerosis	0.00159	0.00462	CcSEcCtD
Avanafil—Flushing—Niacin—atherosclerosis	0.00158	0.00459	CcSEcCtD
Avanafil—Flushing—Pravastatin—atherosclerosis	0.00156	0.00452	CcSEcCtD
Avanafil—Cardiac disorder—Pravastatin—atherosclerosis	0.00156	0.00452	CcSEcCtD
Avanafil—Muscle spasms—Simvastatin—atherosclerosis	0.00155	0.00451	CcSEcCtD
Avanafil—Vertigo—Lovastatin—atherosclerosis	0.00155	0.00451	CcSEcCtD
Avanafil—Angiopathy—Niacin—atherosclerosis	0.00155	0.00449	CcSEcCtD
Avanafil—Vision blurred—Simvastatin—atherosclerosis	0.00152	0.00442	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00152	0.0044	CcSEcCtD
Avanafil—Insomnia—Rosuvastatin—atherosclerosis	0.00151	0.00437	CcSEcCtD
Avanafil—Palpitations—Ezetimibe—atherosclerosis	0.0015	0.00435	CcSEcCtD
Avanafil—Malnutrition—Niacin—atherosclerosis	0.00148	0.00431	CcSEcCtD
Avanafil—Cough—Ezetimibe—atherosclerosis	0.00148	0.00429	CcSEcCtD
Avanafil—Arthralgia—Lovastatin—atherosclerosis	0.00147	0.00427	CcSEcCtD
Avanafil—Chest pain—Lovastatin—atherosclerosis	0.00147	0.00427	CcSEcCtD
Avanafil—Myalgia—Lovastatin—atherosclerosis	0.00147	0.00427	CcSEcCtD
Avanafil—Dyspepsia—Rosuvastatin—atherosclerosis	0.00147	0.00425	CcSEcCtD
Avanafil—Hypertension—Ezetimibe—atherosclerosis	0.00146	0.00425	CcSEcCtD
Avanafil—Vertigo—Simvastatin—atherosclerosis	0.00145	0.00421	CcSEcCtD
Avanafil—Arthralgia—Ezetimibe—atherosclerosis	0.00144	0.00419	CcSEcCtD
Avanafil—Chest pain—Ezetimibe—atherosclerosis	0.00144	0.00419	CcSEcCtD
Avanafil—Myalgia—Ezetimibe—atherosclerosis	0.00144	0.00419	CcSEcCtD
Avanafil—Dry mouth—Lovastatin—atherosclerosis	0.00144	0.00418	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00143	0.00416	CcSEcCtD
Avanafil—Muscle spasms—Niacin—atherosclerosis	0.00143	0.00414	CcSEcCtD
Avanafil—Constipation—Rosuvastatin—atherosclerosis	0.00142	0.00413	CcSEcCtD
Avanafil—Dry mouth—Ezetimibe—atherosclerosis	0.00141	0.0041	CcSEcCtD
Avanafil—Muscle spasms—Pravastatin—atherosclerosis	0.00141	0.00408	CcSEcCtD
Avanafil—Infection—Lovastatin—atherosclerosis	0.0014	0.00407	CcSEcCtD
Avanafil—Vision blurred—Niacin—atherosclerosis	0.0014	0.00406	CcSEcCtD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—atherosclerosis	0.00139	0.066	CbGpPWpGaD
Avanafil—Vision blurred—Pravastatin—atherosclerosis	0.00138	0.004	CcSEcCtD
Avanafil—Myalgia—Simvastatin—atherosclerosis	0.00138	0.00399	CcSEcCtD
Avanafil—Chest pain—Simvastatin—atherosclerosis	0.00138	0.00399	CcSEcCtD
Avanafil—Arthralgia—Simvastatin—atherosclerosis	0.00138	0.00399	CcSEcCtD
Avanafil—Infection—Ezetimibe—atherosclerosis	0.00137	0.00399	CcSEcCtD
Avanafil—Nervous system disorder—Ezetimibe—atherosclerosis	0.00136	0.00394	CcSEcCtD
Avanafil—Skin disorder—Ezetimibe—atherosclerosis	0.00134	0.0039	CcSEcCtD
Avanafil—Vertigo—Niacin—atherosclerosis	0.00133	0.00387	CcSEcCtD
Avanafil—Vertigo—Pravastatin—atherosclerosis	0.00131	0.00381	CcSEcCtD
Avanafil—Palpitations—Niacin—atherosclerosis	0.00131	0.00381	CcSEcCtD
Avanafil—Infection—Simvastatin—atherosclerosis	0.00131	0.0038	CcSEcCtD
Avanafil—CYP3A4—liver—atherosclerosis	0.00131	0.0113	CbGeAlD
Avanafil—Cough—Niacin—atherosclerosis	0.0013	0.00376	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00129	0.00373	CcSEcCtD
Avanafil—Insomnia—Lovastatin—atherosclerosis	0.00128	0.0037	CcSEcCtD
Avanafil—Cough—Pravastatin—atherosclerosis	0.00128	0.0037	CcSEcCtD
Avanafil—Arthralgia—Niacin—atherosclerosis	0.00126	0.00367	CcSEcCtD
Avanafil—Myalgia—Niacin—atherosclerosis	0.00126	0.00367	CcSEcCtD
Avanafil—Hypertension—Pravastatin—atherosclerosis	0.00126	0.00366	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00126	0.00366	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00126	0.00364	CcSEcCtD
Avanafil—Insomnia—Ezetimibe—atherosclerosis	0.00125	0.00363	CcSEcCtD
Avanafil—Arthralgia—Pravastatin—atherosclerosis	0.00124	0.00361	CcSEcCtD
Avanafil—Chest pain—Pravastatin—atherosclerosis	0.00124	0.00361	CcSEcCtD
Avanafil—Myalgia—Pravastatin—atherosclerosis	0.00124	0.00361	CcSEcCtD
Avanafil—Dyspepsia—Lovastatin—atherosclerosis	0.00124	0.0036	CcSEcCtD
Avanafil—Dry mouth—Niacin—atherosclerosis	0.00124	0.00359	CcSEcCtD
Avanafil—Dyspepsia—Ezetimibe—atherosclerosis	0.00122	0.00353	CcSEcCtD
Avanafil—Fatigue—Lovastatin—atherosclerosis	0.00122	0.00353	CcSEcCtD
Avanafil—Constipation—Lovastatin—atherosclerosis	0.00121	0.0035	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.0012	0.00349	CcSEcCtD
Avanafil—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00119	0.00347	CcSEcCtD
Avanafil—Asthenia—Rosuvastatin—atherosclerosis	0.00119	0.00347	CcSEcCtD
Avanafil—Insomnia—Simvastatin—atherosclerosis	0.00119	0.00346	CcSEcCtD
Avanafil—Fatigue—Ezetimibe—atherosclerosis	0.00119	0.00346	CcSEcCtD
Avanafil—Infection—Pravastatin—atherosclerosis	0.00119	0.00344	CcSEcCtD
Avanafil—Constipation—Ezetimibe—atherosclerosis	0.00118	0.00343	CcSEcCtD
Avanafil—Tachycardia—Niacin—atherosclerosis	0.00118	0.00343	CcSEcCtD
Avanafil—Pruritus—Rosuvastatin—atherosclerosis	0.00118	0.00342	CcSEcCtD
Avanafil—Skin disorder—Niacin—atherosclerosis	0.00118	0.00341	CcSEcCtD
Avanafil—Dyspepsia—Simvastatin—atherosclerosis	0.00116	0.00337	CcSEcCtD
Avanafil—CYP3A4—Liver X Receptor Pathway—ABCG8—atherosclerosis	0.00115	0.055	CbGpPWpGaD
Avanafil—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00114	0.00331	CcSEcCtD
Avanafil—Diarrhoea—Rosuvastatin—atherosclerosis	0.00114	0.0033	CcSEcCtD
Avanafil—Fatigue—Simvastatin—atherosclerosis	0.00114	0.0033	CcSEcCtD
Avanafil—Hypotension—Niacin—atherosclerosis	0.00113	0.00329	CcSEcCtD
Avanafil—Constipation—Simvastatin—atherosclerosis	0.00113	0.00327	CcSEcCtD
Avanafil—Body temperature increased—Lovastatin—atherosclerosis	0.00112	0.00324	CcSEcCtD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS3—atherosclerosis	0.00111	0.0531	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Niacin—atherosclerosis	0.0011	0.0032	CcSEcCtD
Avanafil—Dizziness—Rosuvastatin—atherosclerosis	0.0011	0.00319	CcSEcCtD
Avanafil—Insomnia—Niacin—atherosclerosis	0.0011	0.00318	CcSEcCtD
Avanafil—Body temperature increased—Ezetimibe—atherosclerosis	0.00109	0.00317	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00109	0.00315	CcSEcCtD
Avanafil—Insomnia—Pravastatin—atherosclerosis	0.00108	0.00313	CcSEcCtD
Avanafil—Somnolence—Niacin—atherosclerosis	0.00108	0.00313	CcSEcCtD
Avanafil—Dyspepsia—Niacin—atherosclerosis	0.00107	0.00309	CcSEcCtD
Avanafil—Dyspepsia—Pravastatin—atherosclerosis	0.00105	0.00305	CcSEcCtD
Avanafil—Rash—Rosuvastatin—atherosclerosis	0.00105	0.00305	CcSEcCtD
Avanafil—Dermatitis—Rosuvastatin—atherosclerosis	0.00105	0.00304	CcSEcCtD
Avanafil—Gastrointestinal disorder—Niacin—atherosclerosis	0.00105	0.00304	CcSEcCtD
Avanafil—Body temperature increased—Simvastatin—atherosclerosis	0.00104	0.00303	CcSEcCtD
Avanafil—Headache—Rosuvastatin—atherosclerosis	0.00104	0.00303	CcSEcCtD
Avanafil—Fatigue—Pravastatin—atherosclerosis	0.00103	0.00298	CcSEcCtD
Avanafil—Constipation—Pravastatin—atherosclerosis	0.00102	0.00296	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ESAM—atherosclerosis	0.00101	0.0483	CbGpPWpGaD
Avanafil—Asthenia—Lovastatin—atherosclerosis	0.00101	0.00294	CcSEcCtD
Avanafil—Pruritus—Lovastatin—atherosclerosis	0.000998	0.0029	CcSEcCtD
Avanafil—Asthenia—Ezetimibe—atherosclerosis	0.000993	0.00288	CcSEcCtD
Avanafil—Nausea—Rosuvastatin—atherosclerosis	0.000989	0.00287	CcSEcCtD
Avanafil—Pruritus—Ezetimibe—atherosclerosis	0.000979	0.00284	CcSEcCtD
Avanafil—Diarrhoea—Lovastatin—atherosclerosis	0.000965	0.0028	CcSEcCtD
Avanafil—Body temperature increased—Niacin—atherosclerosis	0.000958	0.00278	CcSEcCtD
Avanafil—Asthenia—Simvastatin—atherosclerosis	0.000947	0.00275	CcSEcCtD
Avanafil—Diarrhoea—Ezetimibe—atherosclerosis	0.000947	0.00275	CcSEcCtD
Avanafil—Body temperature increased—Pravastatin—atherosclerosis	0.000943	0.00274	CcSEcCtD
Avanafil—Pruritus—Simvastatin—atherosclerosis	0.000934	0.00271	CcSEcCtD
Avanafil—Dizziness—Lovastatin—atherosclerosis	0.000933	0.00271	CcSEcCtD
Avanafil—Dizziness—Ezetimibe—atherosclerosis	0.000915	0.00265	CcSEcCtD
Avanafil—Diarrhoea—Simvastatin—atherosclerosis	0.000903	0.00262	CcSEcCtD
Avanafil—Vomiting—Lovastatin—atherosclerosis	0.000897	0.0026	CcSEcCtD
Avanafil—Rash—Lovastatin—atherosclerosis	0.00089	0.00258	CcSEcCtD
Avanafil—Dermatitis—Lovastatin—atherosclerosis	0.000889	0.00258	CcSEcCtD
Avanafil—Headache—Lovastatin—atherosclerosis	0.000884	0.00256	CcSEcCtD
Avanafil—Vomiting—Ezetimibe—atherosclerosis	0.00088	0.00255	CcSEcCtD
Avanafil—Dizziness—Simvastatin—atherosclerosis	0.000873	0.00253	CcSEcCtD
Avanafil—Rash—Ezetimibe—atherosclerosis	0.000873	0.00253	CcSEcCtD
Avanafil—Dermatitis—Ezetimibe—atherosclerosis	0.000872	0.00253	CcSEcCtD
Avanafil—Asthenia—Niacin—atherosclerosis	0.000869	0.00252	CcSEcCtD
Avanafil—Headache—Ezetimibe—atherosclerosis	0.000867	0.00252	CcSEcCtD
Avanafil—Pruritus—Niacin—atherosclerosis	0.000857	0.00249	CcSEcCtD
Avanafil—Asthenia—Pravastatin—atherosclerosis	0.000856	0.00248	CcSEcCtD
Avanafil—Pruritus—Pravastatin—atherosclerosis	0.000844	0.00245	CcSEcCtD
Avanafil—Vomiting—Simvastatin—atherosclerosis	0.000839	0.00243	CcSEcCtD
Avanafil—Nausea—Lovastatin—atherosclerosis	0.000838	0.00243	CcSEcCtD
Avanafil—Rash—Simvastatin—atherosclerosis	0.000832	0.00241	CcSEcCtD
Avanafil—Dermatitis—Simvastatin—atherosclerosis	0.000831	0.00241	CcSEcCtD
Avanafil—Diarrhoea—Niacin—atherosclerosis	0.000829	0.00241	CcSEcCtD
Avanafil—CYP3A4—Liver X Receptor Pathway—CYP7A1—atherosclerosis	0.000827	0.0394	CbGpPWpGaD
Avanafil—Headache—Simvastatin—atherosclerosis	0.000827	0.0024	CcSEcCtD
Avanafil—Nausea—Ezetimibe—atherosclerosis	0.000822	0.00238	CcSEcCtD
Avanafil—Diarrhoea—Pravastatin—atherosclerosis	0.000816	0.00237	CcSEcCtD
Avanafil—Dizziness—Niacin—atherosclerosis	0.000801	0.00232	CcSEcCtD
Avanafil—Dizziness—Pravastatin—atherosclerosis	0.000789	0.00229	CcSEcCtD
Avanafil—Nausea—Simvastatin—atherosclerosis	0.000784	0.00227	CcSEcCtD
Avanafil—Vomiting—Niacin—atherosclerosis	0.00077	0.00224	CcSEcCtD
Avanafil—Rash—Niacin—atherosclerosis	0.000764	0.00222	CcSEcCtD
Avanafil—Dermatitis—Niacin—atherosclerosis	0.000763	0.00221	CcSEcCtD
Avanafil—Headache—Niacin—atherosclerosis	0.000759	0.0022	CcSEcCtD
Avanafil—Vomiting—Pravastatin—atherosclerosis	0.000759	0.0022	CcSEcCtD
Avanafil—Rash—Pravastatin—atherosclerosis	0.000752	0.00218	CcSEcCtD
Avanafil—Dermatitis—Pravastatin—atherosclerosis	0.000752	0.00218	CcSEcCtD
Avanafil—Headache—Pravastatin—atherosclerosis	0.000747	0.00217	CcSEcCtD
Avanafil—PDE5A—Platelet homeostasis—APOB—atherosclerosis	0.000723	0.0345	CbGpPWpGaD
Avanafil—Nausea—Niacin—atherosclerosis	0.00072	0.00209	CcSEcCtD
Avanafil—CYP3A4—Liver X Receptor Pathway—ABCG5—atherosclerosis	0.000716	0.0341	CbGpPWpGaD
Avanafil—Nausea—Pravastatin—atherosclerosis	0.000709	0.00206	CcSEcCtD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—CYP7A1—atherosclerosis	0.000541	0.0258	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—NOS2—atherosclerosis	0.000539	0.0257	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—OLR1—atherosclerosis	0.000533	0.0254	CbGpPWpGaD
Avanafil—CYP3A4—Farnesoid X Receptor  Pathway—CYP7A1—atherosclerosis	0.000495	0.0236	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—atherosclerosis	0.000454	0.0216	CbGpPWpGaD
Avanafil—PDE5A—Platelet homeostasis—NOS3—atherosclerosis	0.000434	0.0207	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINC1—atherosclerosis	0.000421	0.0201	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—F3—atherosclerosis	0.000353	0.0168	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG1—atherosclerosis	0.000343	0.0163	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—F5—atherosclerosis	0.000335	0.0159	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SELP—atherosclerosis	0.000335	0.0159	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CLU—atherosclerosis	0.000319	0.0152	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP7A1—atherosclerosis	0.000311	0.0148	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—THBD—atherosclerosis	0.0003	0.0143	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SELE—atherosclerosis	0.000284	0.0136	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—atherosclerosis	0.000269	0.0128	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VWF—atherosclerosis	0.000254	0.0121	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—F7—atherosclerosis	0.000242	0.0115	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAT—atherosclerosis	0.000216	0.0103	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—GSTM1—atherosclerosis	0.000213	0.0102	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7A1—atherosclerosis	0.000197	0.0094	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP7A1—atherosclerosis	0.000195	0.00927	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—KNG1—atherosclerosis	0.000189	0.00902	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAUR—atherosclerosis	0.000188	0.00894	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLG—atherosclerosis	0.000183	0.00874	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—atherosclerosis	0.000182	0.00869	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—atherosclerosis	0.00018	0.00857	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SOD1—atherosclerosis	0.000176	0.00837	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IGF2—atherosclerosis	0.000167	0.00795	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—APOB—atherosclerosis	0.000162	0.00772	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.00016	0.00765	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.00016	0.00762	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PRKCG—atherosclerosis	0.00015	0.00717	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.000148	0.00704	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CD36—atherosclerosis	0.000147	0.00701	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PDGFB—atherosclerosis	0.000136	0.00646	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—MMP1—atherosclerosis	0.000134	0.00639	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CAV1—atherosclerosis	0.000129	0.00612	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—APOA1—atherosclerosis	0.000128	0.00611	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—F2—atherosclerosis	0.000122	0.00583	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS2—atherosclerosis	0.000121	0.00576	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PIK3CG—atherosclerosis	0.000117	0.00558	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.000111	0.0053	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IGF1—atherosclerosis	0.000107	0.00511	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINE1—atherosclerosis	0.000102	0.00485	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ALB—atherosclerosis	0.000102	0.00484	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS3—atherosclerosis	9.72e-05	0.00463	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	9.19e-05	0.00438	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP7A1—atherosclerosis	8.49e-05	0.00405	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP7A1—atherosclerosis	8.38e-05	0.00399	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP27A1—atherosclerosis	7.85e-05	0.00374	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP27A1—atherosclerosis	7.74e-05	0.00369	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFA—atherosclerosis	7e-05	0.00334	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—MAPK3—atherosclerosis	6.62e-05	0.00316	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TGFB1—atherosclerosis	6.43e-05	0.00306	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—AKT1—atherosclerosis	4.47e-05	0.00213	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	3.51e-05	0.00167	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	3.46e-05	0.00165	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	2.49e-05	0.00118	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PLTP—atherosclerosis	2.34e-05	0.00111	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCG8—atherosclerosis	2.03e-05	0.000966	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LTA4H—atherosclerosis	2.03e-05	0.000966	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.6e-05	0.000763	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—FABP4—atherosclerosis	1.51e-05	0.000718	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LCAT—atherosclerosis	1.51e-05	0.000718	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOA4—atherosclerosis	1.48e-05	0.000705	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.45e-05	0.000692	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.34e-05	0.00064	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOA2—atherosclerosis	1.27e-05	0.000606	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.27e-05	0.000606	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.27e-05	0.000606	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.27e-05	0.000606	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.26e-05	0.000599	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LPA—atherosclerosis	1.21e-05	0.000579	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—BGN—atherosclerosis	1.18e-05	0.00056	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOA5—atherosclerosis	1.16e-05	0.000555	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.12e-05	0.000534	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.08e-05	0.000516	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NAMPT—atherosclerosis	9.71e-06	0.000463	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LIPC—atherosclerosis	9.65e-06	0.00046	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOC3—atherosclerosis	9.59e-06	0.000457	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LDLR—atherosclerosis	9.53e-06	0.000454	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CETP—atherosclerosis	9.31e-06	0.000443	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SCARB1—atherosclerosis	8.91e-06	0.000425	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMGCR—atherosclerosis	8.42e-06	0.000401	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCA1—atherosclerosis	7.5e-06	0.000357	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMOX1—atherosclerosis	6.44e-06	0.000307	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOB—atherosclerosis	6.16e-06	0.000294	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM1—atherosclerosis	6e-06	0.000286	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LPL—atherosclerosis	5.89e-06	0.00028	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GPX1—atherosclerosis	5.74e-06	0.000274	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CD36—atherosclerosis	5.59e-06	0.000266	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTHFR—atherosclerosis	5.3e-06	0.000253	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARA—atherosclerosis	5.2e-06	0.000248	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AGT—atherosclerosis	5.04e-06	0.00024	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOE—atherosclerosis	4.93e-06	0.000235	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CAV1—atherosclerosis	4.89e-06	0.000233	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APOA1—atherosclerosis	4.88e-06	0.000232	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CG—atherosclerosis	4.45e-06	0.000212	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARG—atherosclerosis	4.3e-06	0.000205	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—INS—atherosclerosis	4.22e-06	0.000201	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALB—atherosclerosis	3.86e-06	0.000184	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NOS3—atherosclerosis	3.7e-06	0.000176	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.38e-06	0.000161	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AKT1—atherosclerosis	1.7e-06	8.1e-05	CbGpPWpGaD
